Cleared Traditional

K771644 - FRAGMATOME MODEL 820

K771644 is an FDA 510(k) clearance for FRAGMATOME MODEL 820, manufactured by Berkeley Bio-Engineering. The device is a Class 2 Ophthalmic device with product code HQC cleared through the Traditional 510(k) pathway after a 28-day FDA review.

K771644 · Berkeley Bio-Engineering · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1977
Decision
28d
Days
Class 2
Risk

K771644 is an FDA 510(k) clearance for the FRAGMATOME MODEL 820. Classified as Unit, Phacofragmentation (product code HQC), Class II - Special Controls.

Submitted by Berkeley Bio-Engineering (Mchenry, US). The FDA issued a Cleared decision on September 26, 1977 after a review of 28 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4670 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Berkeley Bio-Engineering devices

FDA 510(k) Submission Details - K771644

510(k) Number K771644 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 29, 1977
Decision Date September 26, 1977
Days to Decision 28 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
82d faster than avg
Panel avg: 110d · This submission: 28d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

HQC Device Classification - Class 2, Special Controls

Product Code HQC Unit, Phacofragmentation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.4670
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.